GlassScriptPhysician profile
Julia Sangiovanni
NPI 1184288722
$4,565.38
in general payments reported to CMS, 2019-2025
42 companies · $729 in 2025
The $729 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,009 · 2022: $97.91 · 2023: $865 · 2024: $865 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,458.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $681.72 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $578.67 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $316.55 | 2023-2025 | Qelbree, Qelbree |
| Astrazeneca Pharmaceuticals LP | $278.21 | 2021-2025 | Airsupra |
| Lilly USA, LLC | $267.12 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amarin Pharma, INC. | $239.19 | 2021 | |
| Tris Pharma INC | $162.10 | 2023-2025 | Dyanavel Xr |
| Exact Sciences Corporation | $143.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $138.53 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $131.47 | 2021 | |
| Glaxosmithkline, LLC. | $112.00 | 2021-2025 | Pediarix, Bexsero, Rotarix |
| Gilead Sciences, INC. | $110.40 | 2023-2025 | |
| Amgen INC. | $109.65 | 2021-2025 | Otezla, Otezla, Repatha |
| Neos Therapeutics, LP | $97.38 | 2023-2024 | Adzenys Xr-Odt |
| Esperion Therapeutics, INC. | $92.58 | 2021-2023 | Nexletol |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Sangiovanni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.